The local government of San Fernando has directed a fuel service provider in the city to explain reported irregular operating ...

Cybersecurity may not directly increase a company’s sale price, but disciplined oversight ensures it does not become a deal ...

Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value ...

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction ...

Enhance OT/ICS resilience with advanced threat detection and rapid response strategies. Learn how to identify, contain, and mitigate cyber risks across control and safety ...

ACI-7104 Phase 2 data and mid-2026 readout, plus FY25 cash burn and dilution risk—see key catalysts and what to do now.

ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today presented new data from the first clinical study in Alzheimer's disease ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...

Wout van Aert carries momentum from crash to go third as Mathieu van der Poel takes eighth after dropping on the Poggio ...

C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation (R), highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...